Drug intelligence / Profile preview

thiotepa + methotrexate

Development stage: Unknown
Lead developer: Sumitomo Pharma
Modality: Small Molecules
Administration: Intravenous

Overview

A combination chemotherapy regimen consisting of thiotepa and high-dose methotrexate (HD-MTX). Thiotepa inhibits tumor growth by disrupting DNA bonds, while methotrexate is an antimetabolite that inhibits dihydrofolate reductase. This combination is primarily used in the treatment of central nervous system lymphoma (CNSL), including primary CNS lymphoma (PCNSL) and secondary CNS lymphoma. The regimen is often administered with other agents such as rituximab and/or Bruton tyrosine kinase (BTK) inhibitors like orelabrutinib or zanubrutinib to enhance efficacy.

Brand names: Tepadina
Other names: thiotepamethotrexateMTXN,N',N''-triethylenethiophosphoramidetriethylenethiophosphoramideThio-TEPA

Targets

DHFR (Dihydrofolate reductase)DNA

Beyond the preview

Go deeper on thiotepa + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thiotepa + methotrexate.

Explore the full profile